

TABLE OF CONTENTS

0. Executive Summary	19
1. Introduction	21
Definitions	21
Historical evolution of gene therapy	21
Relation of gene therapy to other biotechnologies.....	23
Molecular biological basics for gene therapy.....	23
Genome.....	23
DNA	24
RNA	24
<i>Alternative RNA splicing</i>	<i>25</i>
Genes.....	26
Gene regulation	26
Gene expression	28
Chromosomes	28
Telomeres.....	29
Mitochondrial DNA.....	29
Proteins	30
2. Gene Therapy Technologies	31
Classification of gene therapy techniques	31
Ex vivo and in vivo gene therapy	32
Ex vivo gene therapy.....	32
In vivo gene therapy	33
Physical methods of gene transfer.....	33
Electroporation	33
Applications of electroporation	34
<i>Clinical applications of electroporation</i>	<i>35</i>
<i>Advantages of electroporation</i>	<i>35</i>
<i>Limitations of electroporation</i>	<i>36</i>
Hydrodynamic	36
Microinjection	36
Particle bombardment	37
Ultrasound-mediated transfection	39
Molecular vibration	39
Application of pulsed magnetic field and superparamagnetic nanoparticles	39
Gene transfection using laser irradiation	40
Photochemical transfection.....	40
Chemical methods of gene transfer.....	41
Gene repair and replacement.....	41
Gene repair by single-stranded oligonucleotides.....	41
History and current status of chimeraplasty.....	42
mRNA gene therapy	42
Spliceosome mediated RNA trans-splicing	42
Vectors for gene therapy	43
Basic considerations	43
Use of genes as pharmaceuticals	44
The ideal vector for gene therapy.....	44
Viral vectors.....	45
<i>Adenovirus vectors.....</i>	<i>46</i>
<i>Adeno-associated virus vectors.....</i>	<i>48</i>
<i>Alphavirus vectors.....</i>	<i>50</i>
<i>Baculovirus vectors</i>	<i>50</i>
<i>Foamy virus vectors</i>	<i>51</i>
<i>Herpes simplex virus vectors</i>	<i>51</i>
<i>Lentiviral vectors</i>	<i>53</i>
<i>Multicistronic retroviral vectors</i>	<i>54</i>
<i>Retroviral vectors.....</i>	<i>55</i>
<i>Oncogenic potential of retroviral vectors</i>	<i>56</i>
<i>Future prospects of viral vectors</i>	<i>57</i>
<i>Companies using viral vectors</i>	<i>57</i>
Nonviral vectors for gene therapy	59
<i>Anionic lipid-DNA complexes.....</i>	<i>59</i>
<i>Cationic lipid-DNA complexes</i>	<i>60</i>
<i>Effects of shape of DNA molecules on delivery with nonviral vectors</i>	<i>60</i>
<i>Electrostatic modifications of surface to improve gene delivery</i>	<i>60</i>
<i>Liposomes for gene therapy</i>	<i>61</i>

<i>Liposome-nucleic acid complexes</i>	62
<i>Liposome-HVJ complex</i>	63
<i>Transposons DNA vectors</i>	63
<i>Polycation-DNA complexes (polyplexes)</i>	64
<i>Plasmid DNA vector for treatment of chronic inflammatory disease</i>	65
<i>Polymer molecules</i>	65
<i>Synthetic biology and DNA vectors</i>	65
<i>Synthetic peptide complexes</i>	66
<i>Future prospects of nonviral vs viral vectors</i>	66
Nanobiotechnology for gene therapy	66
<i>Antisense nanoparticles for gene regulation</i>	67
<i>Biological nanoparticle technology</i>	67
<i>Dendrimers</i>	67
<i>Cochleates</i>	67
<i>Calcium phosphate nanoparticles as nonviral vectors</i>	68
<i>Gelatin nanoparticles for gene delivery</i>	68
<i>Lipid nanoparticles for nucleic acid delivery</i>	69
<i>Nanoparticles as nonviral vectors for gene therapy</i>	69
<i>Nanoparticles with virus-like function as gene therapy vectors</i>	70
<i>Nanobiotistics for nucleic acid delivery</i>	70
<i>Nonionic polymeric micelles for oral gene delivery</i>	70
<i>Silica nanoparticles as a nonviral vector for gene delivery</i>	71
Receptor-mediated endocytosis	71
Artificial viral vectors	72
Directed evolution of AAV to create efficient gene delivery vectors	73
Bacterial ghosts as DNA delivery systems	73
Bacteria plus nanoparticles for gene delivery into cells.....	73
Chromosome-based vectors for gene therapy	74
<i>Mammalian artificial chromosomes (MACs)</i>	75
<i>Artificial Chromosome Expression (ACE)</i>	75
<i>Human artificial chromosomes (HACs)</i>	75
<i>ΦC31 integrase system</i>	76
Companies using nonviral vectors	76
Concluding remarks about vectors	77
Cell-mediated gene therapy	78
<i>Fibroblasts</i>	79
<i>Skeletal muscle cells</i>	79
<i>Vascular smooth muscle cells</i>	80
<i>Keratinocytes</i>	80
<i>Hepatocytes</i>	80
<i>Lymphocytes</i>	81
<i>Regulating protein delivery by genetically encoded lymphocytes</i>	81
Implantation of microencapsulated genetically modified cells	81
Stem cell gene therapy	82
<i>Therapeutic applications for hematopoietic stem cell gene transfer</i>	82
<i>Improving delivery of genes to stem cells</i>	83
<i>Lentiviral vectors for gene transfer to marrow stem cells</i>	83
<i>Use of mesenchymal stem cells for gene therapy</i>	83
<i>Microporation for transfection of MSCs</i>	83
<i>In utero gene therapy using stem cells</i>	84
<i>Gene delivery to stem cells by artificial chromosome expression</i>	84
<i>Linker based sperm-mediated gene transfer technology</i>	84
<i>Combination of gene therapy with therapeutic cloning</i>	84
<i>Expansion of transduced HSCs in vivo</i>	85
<i>The future of hematopoietic stem cell gene therapy</i>	85
Routes of administration for gene therapy	85
<i>Direct injection of naked DNA</i>	86
<i>Intramuscular injection</i>	86
<i>Intravenous DNA injection</i>	86
<i>Intraarterial delivery</i>	87
<i>Companies with gene delivery devices/ technologies</i>	87
Targeted gene therapy	88
<i>Targeted integration</i>	88
<i>Bacteriophage integrase system for site-specific gene delivery</i>	89
<i>Controlled-release delivery of DNA</i>	89
Controlled gene therapy	90
<i>Controlled delivery of genetic material</i>	90
<i>Controlled induction of gene expression</i>	90
<i>Drug-inducible systems for control of gene expression</i>	91
<i>Timed activation of gene therapy by a circuit based on signaling network</i>	91
<i>Small molecules for post-transcriptional regulation of gene expression</i>	91

Engineered zinc finger DNA binding proteins for gene correction	92
Light Activated Gene Therapy	92
Spatial control of gene expression via local hyperthermia	92
Companies with regulated /targeted gene therapy	93
Gene marking	94
Germline gene therapy	94
Potential applications of human germline genome modification	94
Pros and cons of human germline genome modification	95
Role of gene transfer in antibody therapy	96
Genetically engineered vaccines	96
DNA vaccines	97
<i>DNA inoculation technology</i>	97
<i>Methods for enhancing the potency of DNA vaccines</i>	98
<i>Advantages of DNA vaccines</i>	98
Vaccine vectors	98
Challenges and limitations of genetically engineered vaccines	99
Vaccines based on reverse genetics	100
Technologies for gene suppression	100
Antisense oligonucleotides	100
Transcription factor decoys	101
Aptamers	102
Ribozymes	102
Peptide nucleic acid	102
<i>Intracellular delivery of PNAs</i>	102
Locked nucleic acid	103
<i>Zorro-LNA</i>	103
Gene silencing	103
Post-transcriptional gene silencing	104
Definitions and terminology of RNAi	104
RNAi mechanisms	104
Inhibition of gene expression by antigene RNA	105
RNAi gene therapy	106
microRNA gene therapy	106
Application of molecular diagnostic methods in gene therapy	106
Use of PCR to study biodistribution of gene therapy vector	107
PCR for verification of the transcription of DNA	107
In situ PCR for direct quantification of gene transfer into cells	107
Detection of retroviruses by reverse transcriptase (RT)-PCR	108
Confirmation of viral vector integration	108
Monitoring of gene expression	108
<i>Monitoring of gene expression by green fluorescent protein</i>	108
<i>Monitoring in vivo gene expression by molecular imaging</i>	109
<i>Advantages of gene therapy compared with protein therapy</i>	109
3. Clinical Applications of Gene Therapy	111
Introduction	111
Bone and joint disorders	111
Bone fractures	111
Gene therapy for intervertebral disc degeneration	112
Spinal fusion	112
Osteogenesis imperfecta	113
Rheumatoid arthritis	113
<i>Local or systemic treatment</i>	114
<i>In vivo or ex vivo gene therapy of RA</i>	114
<i>Clinical trials</i>	115
Gene therapy for osteoarthritis	116
Sports injuries	117
<i>Repair of articular cartilage defects</i>	117
Regeneration and replacement of bone by gene therapy	118
Bacterial infections	119
Antisense approach to bacterial infections	119
Dentistry	119
Tissue engineering in dental implant defects	119
Endocrine and metabolic disorders	120
Introduction	120
Gene therapy of obesity	120
<i>Ad viral vector-mediated transfer of leptin gene</i>	120
<i>AAV vector-mediated delivery of GDNF for obesity</i>	121
Diabetes mellitus	121
Methods of gene therapy of diabetes mellitus	122
<i>Viral vector-mediated gene transfer in diabetes</i>	122

Gene delivery with ultrasonic microbubble destruction technology	123
Genetically engineered cells for diabetes mellitus	123
Genetically altered liver cells	124
Genetically modified stem cells	124
Genetically engineered dendritic cells	124
Insertion of gene encoding for IL-4	124
Leptin gene therapy	125
Concluding remarks about cell and gene therapy of diabetes	125
Gene therapy of growth-hormone deficiency	126
Gastrointestinal disorders	126
Introduction	126
Methods of gene transfer to the gastrointestinal tract	127
Direct delivery of genes	127
Naked plasmid DNA into the submucosa	127
Viral vectors	127
Receptor-mediated endocytosis	128
Indications for gastrointestinal gene therapy	128
Gene therapy for inflammatory disorders of the bowel	128
Gene transfer to the salivary glands	129
Potential clinical applications of salivary gene therapy	130
Hematology	130
Hemophilias	130
Gene therapy of hemophilia	131
Hemophilia A	131
Hemophilia B	132
Concluding remarks about gene therapy of hemophilias	133
Hemoglobinopathies	133
Stem cell-based gene therapy and RNAi for sickle cell disease	134
Gene therapy for β -thalassemia	135
Gene therapy of Fanconi's anemia	136
Acquired hematopoietic disorders	136
Chronic acquired anemias	137
Neutropenia	137
Thrombocytopenia	138
Concluding remarks about gene therapy of hemoglobinopathies	139
Companies involved in gene therapy of hematological disorders	139
In utero/fetal gene therapy	139
Fetal gene transfer techniques	140
Animal models of fetal gene therapy	141
Potential applications of fetal gene therapy	141
Fetal gene therapy for cystic fibrosis	141
Fetal intestinal gene therapy	142
Hearing disorders	142
Potential of gene therapy	142
Vectors for gene therapy of hearing disorders	143
Auditory hair cell replacement and hearing improvement by gene therapy	143
Kidney diseases	144
End-stage renal disease	144
Methods of gene delivery to the kidney	144
Gene transfer into kidney by adenoviral vectors	145
Non-viral gene transfer to the kidneys	145
Gene transfer into the glomerulus by HVJ-liposome	145
Bone marrow stem cells for renal disease	145
Mesangial cell therapy	146
Liposome-mediated gene transfer into the tubules	146
Gene transfer to tubules with cationic polymer polyethylenimine	146
Gene therapy in animal experimental models of renal disease	147
Genetic manipulations of the embryonic kidney	147
Antisense intervention in glomerulonephritis	147
Gene therapy for renal fibrosis	148
Use of genetically engineered cells for uremia due to renal failure	148
Concluding remarks	149
Liver disorders	149
Techniques of gene delivery to liver	150
Direct injection of DNA into liver	150
Local gene delivery by isolated organ perfusion	150
Liposome-mediated direct gene transfer	150
Retroviral vector for gene transfer to liver	151
Adenoviral vectors for gene transfer to liver	151
Receptor-mediated approach	151
Cell therapy for liver disorders	151

<i>Transplantation of genetically modified hepatocytes</i>	152
<i>Genetically modified hematopoietic stem cells</i>	152
<i>Gene therapy by ex vivo transduced liver progenitor cells</i>	152
Gene therapy of genetic diseases affecting the liver	153
<i>Crigler-Najjar syndrome</i>	153
<i>Hereditary tyrosinemia type I (HT1)</i>	153
<i>Hereditary tyrosinemia type 3</i>	153
Gene therapy of acquired diseases affecting the liver.....	154
<i>Cirrhosis of liver</i>	154
Ophthalmic disorders	154
Introduction to gene therapy of ophthalmic disorders	154
Degenerative retinal disorders	155
<i>Age-related macular degeneration</i>	155
<i>Inherited retinal degenerations</i>	157
Inherited disorders affecting vision	157
<i>Gene therapy for color blindness</i>	157
<i>Leber congenital amaurosis</i>	158
<i>Retinitis pigmentosa</i>	159
<i>Stargardt disease</i>	160
<i>Usher syndrome</i>	160
<i>X-linked juvenile retinoschisis</i>	160
Proliferative retinopathies	161
Methods of gene transfer to retinal cells.....	161
<i>DNA nanoparticles for nonviral gene transfer to the eye</i>	162
Prevention of complications associated with eye surgery	162
<i>Prevention of proliferative retinopathy by gene therapy</i>	162
<i>DNA nanoparticles for gene therapy of retinal degenerative disorders</i>	163
<i>Posterior capsule opacification after cataract surgery</i>	163
Autoimmune uveitis	163
Retinal ischemic injury	164
Corneal disorders	164
Glaucoma	165
Disorders of hearing	165
Gene therapy for hearing loss.....	165
Organ transplantation	166
Introduction	166
DNA vaccines for transplantation	166
Gene therapy for prolonging allograft survival	166
Gene therapy in lung transplantation.....	167
Role of gene therapy in liver transplantation.....	167
Gene therapy in kidney transplantation.....	167
Veto cells and transplant tolerance	168
Pulmonary disorders	168
Techniques of gene delivery to the lungs.....	169
<i>Adenoviral vectors</i>	169
<i>Non-viral vectors</i>	170
<i>Aerosolization as an aid to gene transfer to lungs</i>	170
Cystic fibrosis	170
<i>Genetics and clinical features</i>	170
<i>Gene therapy for CF</i>	171
<i>CFTR gene transfer in CF</i>	171
<i>Concluding remarks about gene therapy of CF</i>	172
Miscellaneous pulmonary disorders	173
<i>Gene therapy for pulmonary arterial hypertension</i>	173
<i>Gene therapy for bleomycin-induced pulmonary fibrosis</i>	174
<i>Pulmonary complications of α1-antitrypsin deficiency</i>	174
<i>Gene therapy for asthma</i>	175
<i>Gene therapy for adult respiratory distress syndrome</i>	176
<i>Gene therapy for lung injury</i>	176
<i>Gene therapy for bronchopulmonary dysplasia</i>	176
Concluding remarks about gene therapy of lungs	177
Companies involved in pulmonary gene therapy	177
Skin and soft tissue disorders	178
Gene transfer to the skin	178
<i>Electroporation for transdermal delivery of plasmid DNA</i>	178
<i>Electroporation for transdermal delivery of DNA vaccines</i>	178
<i>Liposomes for transdermal gene delivery</i>	179
<i>Ultrasound and topical gene therapy</i>	179
Gene therapy in skin disorders	179
<i>Gene therapy of hair loss</i>	179
<i>Gene therapy for xeroderma pigmentosa</i>	180

Gene therapy for lamellar ichthyosis.....	180
Gene therapy for epidermolysis bullosa.....	180
Gene transfer techniques for wound healing.....	181
Urogenital disorders	182
Gene therapy for urinary tract dysfunction.....	182
Gene therapy for erectile dysfunction.....	182
<i>NOS gene transfer for erectile dysfunction</i>	<i>182</i>
<i>Clinical trial of hMaxi-K Gene transfer in erectile dysfunction</i>	<i>182</i>
<i>Gene therapy for erectile dysfunction due to nerve injury.....</i>	<i>183</i>
<i>Concluding remarks on gene therapy for erectile dysfunction.....</i>	<i>183</i>
Veterinary gene therapy	183
Gene therapy for mucopolysaccharidosis VII in dogs.....	184
Gene therapy to increase disease resistance.....	184
Gene therapy for infections.....	184
Gene therapy for chronic anemia.....	185
Gene therapy for endocrine disorders.....	185
Gene therapy for arthritis.....	185
Cancer gene therapy.....	186
<i>Brain tumors in cats and dogs</i>	<i>186</i>
<i>Breast cancer in dogs</i>	<i>187</i>
<i>Canine hemangiosarcoma</i>	<i>187</i>
<i>Canine melanoma</i>	<i>188</i>
<i>Canine soft tissue sarcoma.....</i>	<i>188</i>
Melanoma in horses.....	188
4. Gene Therapy of Genetic Disorders.....	189
Introduction.....	189
Primary immunodeficiency disorders	190
Severe combined immune deficiency.....	191
Chronic granulomatous disease.....	193
Wiskott-Aldrich syndrome.....	193
Purine nucleoside phosphorylase deficiency.....	194
Major histocompatibility class II deficiency.....	194
Future prospects of gene therapy of inherited immunodeficiencies.....	195
Metabolic disorders.....	195
Adrenoleukodystrophy.....	196
Canavan disease.....	196
Lesch-Nyhan syndrome.....	197
LPL deficiency.....	197
Ornithine transcarbamylase deficiency.....	198
Phenylketonuria.....	198
Porphyrias.....	199
Tetrahydrobiopterin deficiency.....	199
Lysosomal storage disorders.	200
Batten disease.....	201
Fabry's disease.....	201
Farber's disease.....	202
Gaucher disease.....	202
<i>Animals models of Gaucher's disease.....</i>	<i>202</i>
<i>Gene therapy of Gaucher's disease.....</i>	<i>203</i>
Hunter syndrome.....	204
Combination of cell and gene therapy for Krabbe's disease.....	204
Metachromatic leukodystrophy.....	205
Mucopolysaccharidosis type 1 (Hurler syndrome).....	205
Niemann-Pick type A disease.....	206
Pompe disease.....	206
Sanfilippo A syndrome.....	207
Sly syndrome.....	207
Tay-Sachs disease.....	207
Future prospects of gene therapy of lysosomal storage disorders.....	208
Trinucleotide repeat disorders	208
Muscular dystrophies	208
Duchenne muscular dystrophy (DMD).....	208
<i>Animal models for gene therapy of DMD</i>	<i>209</i>
<i>Antisense approach to DMD.....</i>	<i>209</i>
<i>Exon-skipping technology for DMD</i>	<i>210</i>
<i>Liposome-mediated gene transfer</i>	<i>210</i>
<i>Myoblast-based gene transfer in DMD.....</i>	<i>211</i>
<i>Plasmid-mediated gene therapy.....</i>	<i>211</i>
<i>Post-transcriptional modulation of gene expression in DMD</i>	<i>211</i>
<i>Repair of dystrophin gene</i>	<i>212</i>

<i>Routes of administration of gene therapy in DMD</i>	212
<i>Types of dystrophin constructs</i>	212
<i>Viral vectors for DMD</i>	213
<i>Conclusions and future prospects of gene therapy of DMD</i>	214
Limb-girdle muscular dystrophy	215
Myotonic dystrophy	215
Spinal muscular atrophy	216
Antisense gene therapy of SMA.....	216
Hereditary neuropathies	216
Charcot-Marie-Tooth disease	216
Hereditary axonal neuropathies of the peripheral nerves.....	217
Gene therapy of mitochondrial disorders	217
Companies involved in gene therapy of genetic disorders	218
5. Gene Therapy of Cancer	219
Strategies for cancer gene therapy	219
Direct gene delivery to the tumor	220
Injection into tumor	220
<i>Direct injection of adenoviral vectors</i>	220
<i>Direct injection of a plasmid DNA-liposome complex</i>	221
<i>A polymer approach to local gene therapy for cancer</i>	221
Electroporation for cancer gene therapy	221
Control of gene expression in tumor by local heat	222
Radiation-guided gene therapy of cancer	222
Radioprotective gene therapy	223
Nanoparticles to facilitate combination of hyperthermia and gene therapy.....	223
Cell-based cancer gene therapy	223
Adoptive cell therapy.....	224
Cytokine gene therapy.....	224
Genetic modification of human hematopoietic stem cells.....	227
Immunogene therapy	227
Cancer vaccines	228
Genetically modified cancer cell vaccines	228
<i>GVAX cancer vaccines</i>	228
<i>Genetically modified dendritic cells</i>	229
Nucleic acid-based cancer vaccines	230
<i>DNA cancer vaccines</i>	230
<i>RNA vaccines</i>	230
Viral vector-based cancer vaccines.....	230
<i>Intradermal delivery of cancer vaccines by Ad vectors</i>	231
Future prospects of cancer vaccines	231
Companies involved in nucleic acid-based cancer vaccines	231
Monoclonal antibody gene transfer for cancer	232
Transfer and expression of intracellular adhesion-1 molecules	233
Other gene-based techniques of immunotherapy of cancer	233
Fas (Apo-1).....	233
Chemokines	233
Major Histocompatibility Complex (MHC) Class I	234
IGF (Insulin-Like Growth Factor).....	234
Inhibition of immunosuppressive function in cancer	234
Delivery of toxic genes to tumor cells for eradication	235
Gene-directed enzyme prodrug therapy	235
Combination of gene therapy with radiotherapy	235
Correction of genetic defects in cancer cells	236
Targeted gene therapy for cancer	236
Antiangiogenic therapy for cancer	236
Bacteria as novel anticancer gene vectors	237
Cancer-specific gene expression	238
Cancer-specific transcription.....	238
Delivery of retroviral particles hitchhiking on T cells	238
Electrogene and electrochemotherapy	239
Epidermal growth factor-mediated DNA delivery	239
Gene-based targeted drug delivery to tumors.....	239
Gene expression in hypoxic tumor cells.....	240
Genetically modified T cells for targeting tumors	240
Genetically engineered stem cells for targeting tumors	241
Hematopoietic stem cells for targeted cancer gene therapy	242
Immunolipoplex for delivery of p53 gene	243
Nanomagnets for targeted cell-based cancer gene therapy.....	243
Nanoparticles for targeted site-specific delivery of anticancer genes	243
Targeted cancer therapy using a dendrimer-based synthetic vector.....	244

Tumor-targeted gene therapy by receptor-mediated endocytosis	244
Virus-mediated oncolysis	244
<i>Cancer terminator virus</i>	244
<i>Cytokine-induced killer cells for delivery of an oncolytic virus</i>	245
<i>Monitoring of viral-mediated oncolysis by PET</i>	246
<i>Oncolytic HSV</i>	246
<i>Oncolytic adenoviruses</i>	246
<i>Oncolytic vesicular stomatitis virus</i>	248
<i>Oncolytic paramyxovirus</i>	248
<i>Oncolytic vaccinia virus</i>	248
<i>Targeted cancer treatments based on oncolytic viruses</i>	248
<i>Concluding remarks on oncolytic gene therapy</i>	249
<i>Companies developing oncolytic viruses</i>	249
Apoptotic approach to improve cancer gene therapy	250
Tumor suppressor gene therapy	250
P53 gene therapy.....	250
BRIT1 gene therapy	251
Nitric oxide-based cancer gene therapy	251
Nitric oxide synthase II DNA injection	251
Gene therapy for radiosensitization of cancer	251
Gene therapy of cancer of selected organs	252
Gene therapy for bladder cancer	252
Gene therapy for glioblastoma multiforme.....	252
<i>Adenoviral vectors for treatment of brain tumors</i>	254
<i>Antiangiogenic gene therapy</i>	254
<i>Autophagy induced by conditionally replicating adenoviruses</i>	255
<i>Baculovirus vector for diphtheria toxin gene therapy</i>	255
<i>Cerepro® (sitimagene ceradenovec)</i>	255
<i>Gene therapy targeting hepatocyte growth factor</i>	256
<i>Genetically engineered MSCs for gene delivery to intracranial gliomas</i>	256
<i>Intravenous gene delivery with nanoparticles into brain tumors</i>	256
<i>Ligand-directed delivery of dsRNA molecules targeted to EGFR</i>	256
<i>RNAi gene therapy of brain cancer</i>	257
<i>Targeting normal brain cells with an AAV vector encoding interferon-β</i>	257
<i>Viral oncolysis of brain tumors</i>	258
Gene therapy for breast cancer.....	258
<i>Gene vaccine for breast cancer</i>	259
<i>Recombinant adenoviral ErbB-2/neu vaccine</i>	259
Gene Therapy for ovarian cancer	260
Gene therapy for malignant melanoma	261
Gene therapy of lung cancer.....	263
<i>Intravenous nanoparticle formulation for delivery of FUS1 gene</i>	263
<i>Aerosol gene delivery for lung cancer</i>	263
Gene therapy for cancer of prostate	264
<i>Experimental studies</i>	264
<i>Nanoparticle-based gene therapy for prostate cancer</i>	264
<i>Tumor suppressor gene therapy in prostate cancer</i>	264
<i>Vaccines for prostate cancer</i>	265
<i>Clinical trials</i>	265
Gene therapy of head and neck cancer	266
<i>Adenoviral vector based P53 gene therapy</i>	266
Gene therapy of pancreatic cancer	266
<i>Rexin-G™ for targeted gene delivery in cancer</i>	267
<i>Targeted Expression of BikDD gene</i>	267
<i>Concluding remarks on gene therapy of pancreatic cancer</i>	267
Cancer gene therapy companies	267
6. Gene Therapy of Neurological Disorders	271
Indications.....	271
Gene transfer techniques for the nervous system	272
Methods of gene transfer to the nervous system	272
Ideal vector for gene therapy of neurological disorders	272
Promoters of gene transfer.....	272
Lentivirus-mediated gene transfer to the CNS.....	273
AAV vector mediated gene therapy for neurogenetic disorders.....	273
Gene transfer to the CNS using recombinant SV40-derived vectors	274
Routes of delivery of genes to the CNS	274
<i>Direct injection into CNS</i>	274
<i>Introduction of the genes into cerebral circulation</i>	275
<i>Introduction of genes into cerebrospinal fluid</i>	275
<i>Intravenous administration of vectors</i>	275

Delivery of gene therapy to the peripheral nervous system	276
Cell-mediated gene therapy of neurological disorders	276
<i>Neuronal cells</i>	276
<i>Neural stem cells and progenitor cells</i>	276
<i>Astrocytes</i>	277
<i>Cerebral endothelial cells</i>	277
<i>Implantation of genetically modified encapsulated cells into the brain</i>	277
Gene therapy of neurodegenerative disorders	277
Gene therapy for Parkinson disease.....	277
Rationale	278
<i>Techniques of gene therapy for PD</i>	279
<i>Delivery of neurotrophic factors by gene therapy</i>	282
<i>Delivery of parkin gene</i>	283
<i>Introduction of functional genes into the brain of patients with PD</i>	283
<i>Nanoparticle-based gene therapy for PD</i>	283
<i>Mitochondrial gene therapy for PD</i>	283
<i>RNAi approach to PD</i>	284
<i>Prospects of gene therapy for PD</i>	284
<i>Companies developing gene therapy for PD</i>	285
Gene therapy for Alzheimer disease	286
Rationale	286
<i>NGF gene therapy for AD</i>	286
<i>FGF2 gene transfer in AD</i>	287
<i>Nepilysin gene therapy</i>	288
<i>Targeting plasminogen activator inhibitor type-1 gene</i>	288
<i>Gene vaccination</i>	288
<i>Combination of gene therapy with other treatments for AD</i>	289
Gene therapy of Huntington disease.....	289
<i>Encapsulated genetically engineered cellular implants</i>	289
<i>Viral vector mediated administration of neurotrophic factors</i>	289
<i>RNAi gene therapy</i>	290
Gene therapy of amyotrophic lateral sclerosis	290
Rationale	290
<i>Technique of gene therapy of ALS</i>	290
Gene therapy of cerebrovascular diseases	291
Preclinical research in gene therapy for cerebrovascular disease	291
Animal models of stroke relevant to gene therapy	292
<i>Transgenic mice as models for stroke</i>	292
<i>Animal models for gene therapy of arteriovenous malformations</i>	292
Gene transfer to cerebral blood vessels.....	293
Gene therapy for vasospasm following subarachnoid hemorrhage	294
<i>NOS gene therapy for cerebral vasospasm</i>	294
Gene therapy for stroke.....	295
<i>Gene therapy for stroke using neurotrophic factors</i>	296
<i>Gene therapy of strokes with a genetic component</i>	296
<i>Gene therapy for intracranial aneurysms</i>	297
<i>RNAi-based gene silencing for neuroprotection in cerebral ischemia</i>	297
Concluding remarks about gene therapy for stroke.....	297
Gene therapy of injuries to the nervous system	298
Traumatic brain injury	298
Spinal cord injury.....	298
Gene therapy of epilepsy	299
Gene therapy for control of seizures	299
Gene therapy for neuroprotection in epilepsy.....	300
Gene therapy for genetic forms of epilepsy	301
Gene therapy for multiple sclerosis.....	301
Gene therapy for relief of pain	302
Rationale of gene therapy for pain	302
Vectors for gene therapy of pain	302
Methods of gene delivery for pain	302
<i>Endogenous analgesic production for cranial neuralgias</i>	303
<i>Gene delivery by intrathecal route</i>	303
<i>Gene transfer for delivery of analgesics to the spinal nerve roots</i>	304
<i>Gene therapy of peripheral neuropathic pain</i>	305
<i>Gene transfer by injections into the brain substance</i>	305
Targets for gene therapy of pain.....	306
<i>Zinc finger DNA-binding protein therapeutic for chronic pain</i>	306
<i>Gene therapy for producing enkephalin to block pain signals</i>	306
<i>Targeting nuclear factor-κB</i>	306
<i>Gene therapy targeted to neuroimmune component of chronic pain</i>	306
Potential applications of gene therapy for management of pain	307

Concluding remarks on gene therapy for pain	307
Gene therapy for psychiatric disorders	308
Gene therapy for depression.....	309
Gene therapy for enhancing cognition after stress	309
Gene therapy against fear disorders	309
Companies involved in gene therapy of neurological disorders	310
7. Gene Therapy of Cardiovascular Disorders	311
Introduction.....	311
Techniques of gene transfer to the cardiovascular system.....	311
Direct plasmid injection into the myocardium	312
Catheter-based systems for vector delivery	312
Ultrasound microbubbles for cardiovascular gene delivery	313
Vectors for cardiovascular gene therapy.....	313
<i>Adenoviral vectors for cardiovascular diseases</i>	<i>313</i>
<i>Plasmid DNA-based delivery in cardiovascular disorders.....</i>	<i>313</i>
<i>Intravenous rAAV vectors for targeted delivery to the heart</i>	<i>314</i>
Hypoxia-regulated gene therapy for myocardial ischemia	314
Angiogenesis and gene therapy of ischemic disorders	314
Therapeutic angiogenesis vs vascular growth factor therapy	315
Gene painting for delivery of targeted gene therapy to the heart.....	315
Gene delivery to vascular endothelium	316
Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles	316
Vascular stents for gene delivery	316
Gene therapy for genetic cardiovascular disorders	317
Genetic disorders predisposing to atherosclerosis.....	317
Familial hypercholesterolemia (FH).....	317
Apolipoprotein E (apoE) deficiency	319
Hypertension	319
Genetic factors for myocardial infarction	320
Acquired cardiovascular diseases	320
Coronary artery disease with angina pectoris.....	320
<i>Ad5FGF-4.....</i>	<i>320</i>
Ischemic heart disease with myocardial infarction	321
<i>Myocardial repair with IGF-1 therapy.....</i>	<i>322</i>
<i>Metalloproteinase-2 inhibitor gene therapy.....</i>	<i>323</i>
<i>miRNA gene therapy for ischemic heart disease</i>	<i>323</i>
Congestive heart failure	323
<i>Rationale of gene therapy in CHF.....</i>	<i>323</i>
<i>β-ARKct gene therapy.....</i>	<i>324</i>
<i>Intracoronary adenovirus-mediated gene therapy for CHF.....</i>	<i>324</i>
<i>AAV-mediated gene transfer for CHF</i>	<i>325</i>
<i>AngioCell gene therapy for CHF.....</i>	<i>325</i>
<i>nNOS gene transfer in CHF.....</i>	<i>326</i>
Cardiomyopathies	326
Cardiac conduction disturbances	326
<i>Gene transfer approaches for biological pacemakers.....</i>	<i>326</i>
<i>Genetically engineered biological pacemakers.....</i>	<i>327</i>
Gene therapy and heart transplantation	327
Peripheral arterial disease	328
Incidence and clinical features	328
Current management	328
Gene therapy for peripheral arterial disease	329
<i>Angiogenesis by gene therapy</i>	<i>329</i>
<i>HIF-1α gene therapy for peripheral arterial disease</i>	<i>329</i>
<i>HGF gene therapy for peripheral arterial disease.....</i>	<i>330</i>
Ischemic neuropathy secondary to peripheral arterial disease.....	330
Prevention of restenosis after angioplasty	330
<i>Antisense approaches</i>	<i>331</i>
<i>Gene therapy to prevent restenosis after angioplasty</i>	<i>331</i>
<i>Techniques of gene therapy for restenosis.....</i>	<i>332</i>
<i>NOS gene therapy for restenosis.....</i>	<i>333</i>
<i>hTIMP-1 gene therapy to prevent intimal hyperplasia</i>	<i>334</i>
Maintaining vascular patency after surgery.....	334
Companies involved in gene therapy of cardiovascular diseases	334
Future prospects of gene therapy of cardiovascular disorders	335
8. Gene therapy of viral infections.....	338
Introduction.....	338
Acquired Immunodeficiency Syndrome (AIDS).....	338
Current management of AIDS.....	338

Gene therapy strategies in HIV/AIDS.....	339
<i>HIV/AIDS vaccines</i>	339
<i>Insertion of protective genes into target cells.</i>	340
Cell/gene therapies for HIV/AIDS	341
<i>Transplantation of genetically modified T-cells</i>	341
<i>Transplantation of genetically modified hematopoietic cells</i>	341
<i>Anti-HIV ribozyme delivered in hematopoietic progenitor cells</i>	342
Inhibition of HIV-1 replication by lentiviral vectors	342
VRX496	342
Intracellular immunization	343
Engineered cellular proteins such as soluble CD4s	343
Intracellular antibodies	343
Anti-rev single chain antibody fragment.....	343
Use of genes to chemosensitize HIV-1 infected cells	344
Autocrine interferon (INF)- β production by somatic cell gene therapy	344
Antisense approaches to AIDS	344
<i>RNA decoys</i>	344
<i>Antisense oligodeoxynucleotides</i>	344
<i>RNA decoys</i>	345
<i>Ribozymes</i>	345
RNAi applications in HIV/AIDS	346
<i>siRNA-directed inhibition of HIV-1 infection</i>	346
<i>Role of the nef gene during HIV-1 infection and RNAi</i>	346
<i>Bispecific siRNA constructs</i>	347
<i>Targeting CXCR4 with siRNAs</i>	347
<i>Targeting CCR5 with siRNAs</i>	347
Companies involved in developing gene therapy for HIV/AIDS	348
Conclusions regarding gene therapy of HIV/AIDS	349
Genetic vaccines for other viral infections	349
Cytomegalic virus infections	349
Viral hepatitis	350
<i>Vaccine for hepatitis B virus</i>	350
<i>Vaccine for hepatitis C virus</i>	351
Vaccine for herpes simplex virus	351
DNA vaccine against rabies	351
DNA vaccine for Ebola	352
Vaccines for avian influenza	352
<i>Future prospects of DNA vaccines for avian influenza</i>	353
<i>Human trial of a DNA vaccine for avian influenza</i>	354
Companies developing genetic vaccines for infections other than AIDS	354
9. Research, Development and Future of Gene Therapy.....	356
Basic research in gene therapy	356
R & D in gene therapy	356
Animal models of human diseases for gene therapy research	357
<i>Lentiviral transgenesis</i>	357
Financing research and development.....	357
Role of the NIH in gene therapy research	357
National Gene Vector Laboratories	357
Financing by the industry	358
Clinical trials in gene therapy	358
Clinical trials worldwide.....	359
<i>Clinical trials in cancer gene therapy</i>	359
<i>Clinical trials in cardiovascular gene therapy</i>	360
<i>Clinical trials in inherited monogenic diseases</i>	360
<i>Clinical trials for other indications</i>	360
Clinical trials in the US	360
Vectors used in gene therapy clinical trials	361
Future prospects for the gene therapy	362
How to improve gene therapy.....	362
Promising areas of application of gene therapy	363
<i>Neurological disorders</i>	363
<i>Gene therapy of cardiovascular disorders</i>	364
<i>Cancer gene therapy</i>	364
Personalized gene therapy	365
10. Regulatory, Safety and Ethical Issues of Gene Therapy.....	367
Regulation of gene therapy in the United States	367
US Federal guidelines for research involving recombinant DNA molecules	367
Regulation of gene therapy in US	367
Office of Biotechnology Activities.....	367

Implantation of genetically manipulated cells.....	368
Clinical trials in gene therapy.....	368
Cell and gene therapy INDs placed on hold by the FDA	368
Regulation of gene therapy in Germany	369
Preclinical research	369
Clinical Trials	369
Marketing authorization	370
Regulation of gene therapy in the United Kingdom	370
Regulation of gene therapy in France	371
Regulation of gene therapy in the Netherlands	371
Regulation of gene therapy in Australia	372
Regulation of gene therapy in Japan	373
Regulation of gene therapy in China	373
Safety issues of gene transfer.....	373
Adverse effects of retroviral vectors	373
<i>Insertional mutagenesis</i>	373
Adverse effects of HSV vectors	374
<i>Neurotoxicity of HSV vectors</i>	374
<i>Hepatotoxicity of HSV-tk/ganciclovir approach</i>	374
Adverse effects of adenoviral vectors.....	374
<i>Inflammatory effects of adenoviruses in lungs</i>	375
<i>Inflammatory effects involving the liver</i>	375
<i>Induction of immune response by adenoviral vectors</i>	375
<i>Impairment of adrenocortical steroidogenesis</i>	376
<i>Adverse effects of AAV vectors</i>	376
Toxicity associated with cationic lipid-mediated gene transfer	376
Toxicity of lipopolysaccharides	377
Potential side effects of RNAi gene therapy.....	377
Role of molecular diagnostics in safety of gene therapy	378
Quality control of vectors	378
<i>Testing for retroviruses</i>	378
<i>Adenoviral vectors</i>	378
<i>Replication competent viruses</i>	378
Genetic characteristics of viral vectors	379
Concluding remarks about safety of viral vectors	379
Ethical aspects of gene therapy	379
The lay consumer's view of somatic gene therapy ethics	380
Ethical aspects of clinical trials.....	380
Ethical aspects of germline gene therapy	381
Germline gene therapy for genetic enhancement	381
Athletic enhancement by genetic engineering	382
<i>Gene doping in sports</i>	382
<i>Gene transfer methods used for enhancing physical performance</i>	382
<i>Adverse effect of genetic engineering</i>	384
<i>Problems in detecting genetic manipulations in athletes</i>	384
<i>Ethical dilemma</i>	384
11. Markets for Gene Therapy	387
Introduction.....	387
Gene therapy markets in various regions of the world.....	387
Gene therapy markets according to therapeutic areas	388
Cancer gene therapy market	388
Markets for gene therapy of genetic disorders	388
Markets for DNA vaccines	389
DNA vaccines markets according to technologies	389
DNA vaccines markets according to therapeutic indications	390
DNA vaccines markets according to geographical areas	390
Competing treatments	391
Antisense	391
RNAi.....	391
Cell therapy	391
Strategies for developing gene therapy markets	392
<i>Collaboration with pharmaceutical companies</i>	392
<i>Collaboration with companies developing cell-based therapies</i>	392
<i>Overcoming obstructions to the development of gene therapy</i>	392
<i>Collaboration with academic gene therapy centers</i>	392
<i>Developing safer and cost-effective gene medicines</i>	392
Unmet needs in gene therapy	393
Promising areas for the development of gene therapy.....	393
Development of gene therapy market in China	394

Tables

Table 1-1: Landmarks in development of gene therapy..... 21

Table 2-1: Classification of methods of gene therapy..... 31

Table 2-2: A comparison of various physical methods of gene transfer 33

Table 2-3: Experimental applications of gene transfer by electroporation 35

Table 2-4: An overview of characteristics of commonly used viral vectors 45

Table 2-5: Companies using viral vectors..... 57

Table 2-6: Companies using nonviral vectors 76

Table 2-7: Target organs for non-viral gene therapy methods. 78

Table 2-8: Potential routes for administration of DNA 85

Table 2-9: Companies with gene delivery devices/ technologies..... 87

Table 2-10: Strategies for targeted gene therapy..... 88

Table 2-11: Animal experimental studies of in vivo gene delivery with polymer systems 89

Table 2-12: Approaches to controlling gene expression in gene therapy..... 90

Table 2-13: Companies with regulated / targeted gene therapy and special techniques 93

Table 2-14: Potential applications of human germline genome modification..... 94

Table 2-15: Applications of molecular diagnostics in gene therapy 107

Table 2-16: Advantages of gene therapy compared with protein therapy 109

Table 3-1: Experimental approaches to gene therapy of rheumatoid arthritis 114

Table 3-2: Gene therapy strategies for osteoarthritis..... 116

Table 3-3: Cell and gene therapy approaches for type 1 diabetes mellitus..... 122

Table 3-4: Indications for gastrointestinal gene therapy 128

Table 3-5: Hematological disorders that can be potentially treated by gene therapy..... 130

Table 3-6: Companies involved in gene therapy of hematological disorders 139

Table 3-7: Techniques of gene transfer to the kidneys..... 144

Table 3-8: Gene therapy in animal experimental models of renal disease..... 147

Table 3-9: Applications of gene therapy in ophthalmological disorders..... 155

Table 3-10: Strategies for gene delivery to the lungs 169

Table 3-11: Companies developing gene therapy for pulmonary disorders 177

Table 4-1: Genetic disorders that are being investigated for gene therapy 189

Table 4-2: X-linked immunodeficiency disorders 191

Table 4-3: Examples of inherited metabolic disorders amenable to gene therapy 195

Table 4-4: Gene therapy approaches to Duchenne muscular dystrophy 209

Table 4-5: Companies involved in gene therapy of genetic/metabolic disorders 218

Table 5-1: Strategies for cancer gene therapy 219

Table 5-2: Cell-based gene therapy for cancer..... 223

Table 5-3: Companies with nucleic acids/genetically modified cell cancer vaccines 231

Table 5-4: Enzyme/prodrug combinations employed in suicide gene therapy 235

Table 5-5: Mutation compensation strategies used clinically 236

Table 5-6: Companies developing oncolytic viruses 249

Table 5-7: Strategies for gene therapy of malignant brain tumors..... 253

Table 5-8: Clinical trials of gene therapy in ovarian cancer..... 260

Table 5-9: Gene therapy for malignant melanoma 261

Table 5-10: Clinical trials of gene therapy for prostate cancer 265

Table 5-11: Companies involved in cancer gene therapy..... 268

Table 6-1: Example of potential indications for gene therapy of neurologic disorder 271

Table 6-2: Methods of gene transfer as applied to neurologic disorders 272

Table 6-3: Gene therapy techniques applicable to Parkinson disease 278

Table 6-4: Companies developing gene therapy for Parkinson's disease 285

Table 6-5: Gene transfer in animal models of carotid artery restenosis 293

Table 6-6: Gene therapy strategies for vasospasm..... 294

Table 6-7: Neuroprotective gene therapy in animal stroke models 295

Table 6-8: Experimental gene therapy approaches for relief of pain 303

Table 6-9: Companies involved in gene therapy of neurological disorders 310

Table 7-1: Cardiovascular disorders for which gene therapy is being considered. 311

Table 7-2: Catheter-based systems for vector delivery to the cardiovascular system 312

Table 7-3: Companies involved in gene therapy of cardiovascular diseases 334

Table 8-1: Strategies for gene therapy of AIDS 339

Table 8-2: Companies involved in developing gene therapy for HIV/AIDS 348

Table 8-3: Companies developing genetic vaccines for infections other than AIDS 354

Table 9-1: Clinical trials of gene therapy in the US according to applications 360

Table 9-2: Potential future applications of gene therapy in disorders of the nervous system 363

Table 10-1: Genes that may be used for performance enhancement 382

Table 11-1: Gene therapy market according to regions/countries – 2011 to 2021 387

Table 11-2: Gene therapy markets according to therapeutic areas – 2011 to 2021..... 388

Table 11-3: Cancer gene therapy market according to type of cancer - 2011 to 2021..... 388

Table 11-4: Gene therapy market for selected genetic disorders - 2011 to 2021	389
Table 11-5: DNA vaccines markets according to technologies - 2011 to 2021	389
Table 11-6: DNA vaccines markets according to therapeutic indications - 2011 to 2021	390
Table 11-7: DNA vaccines markets according to geographical areas - 2011 to 2021	390

Figures

Figure 1-1: Relation of gene therapy to other biotechnologies	23
Figure 1-2: Relationship of DNA, RNA and protein in the cell	27
Figure 2-1: Ex vivo and in vivo techniques of gene therapy	32
Figure 2-2: Structure of the Helios gene gun	37
Figure 2-3: Cochleate-mediated gene therapy	68
Figure 2-4: Bacteria plus nanoparticles for drug delivery into cells	74
Figure 2-5: Schematic of suppression of gene expression by RNAi	105
Figure 6-1: Effect of tyrosine hydroxylase gene delivery on dopamine levels	279
Figure 6-2: Role of cell and gene therapy in stroke according to pathology and stage	297
Figure 9-1: Product development cycle in gene therapy	356
Figure 9-2: Proportions of therapeutic areas in clinical trials of gene therapy in the US	361
Figure 9-3: Proportions of various vectors used in gene therapy trials	361
Figure 11-1: Unmet needs in gene therapy	393